222 related articles for article (PubMed ID: 33732316)
1. Cost-effectiveness analysis of different sequences of osimertinib administration for epidermal growth factor receptor-mutated non-small-cell lung cancer.
Li W; Qian L; Li W; Chen X; He H; Tian H; Zhao Y; Wang X; Cui J
Exp Ther Med; 2021 Apr; 21(4):343. PubMed ID: 33732316
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
Aguiar PN; Haaland B; Park W; San Tan P; Del Giglio A; de Lima Lopes G
JAMA Oncol; 2018 Aug; 4(8):1080-1084. PubMed ID: 29852038
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China.
Shu Y; Ding Y; He X; Liu Y; Wu P; Zhang Q
Front Pharmacol; 2022; 13():920479. PubMed ID: 36204237
[No Abstract] [Full Text] [Related]
4. Osimertinib versus platinum-pemetrexed in patients with previously treated EGFR T790M advanced non-small cell lung cancer: An updated AURA3 trial-based cost-effectiveness analysis.
Shi Y; Pei R; Liu S
Front Oncol; 2022; 12():833773. PubMed ID: 36324594
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR-Mutation-Positive Non-Small Cell Lung Cancer.
Wu B; Gu X; Zhang Q; Xie F
Oncologist; 2019 Mar; 24(3):349-357. PubMed ID: 30257889
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia.
Khoo T; Gao L
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):415-423. PubMed ID: 33151783
[No Abstract] [Full Text] [Related]
7. Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR TKI Therapy.
Wu B; Gu X; Zhang Q
J Thorac Oncol; 2018 Feb; 13(2):184-193. PubMed ID: 29101057
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations.
Holleman MS; Al MJ; Zaim R; Groen HJM; Uyl-de Groot CA
Eur J Health Econ; 2020 Feb; 21(1):153-164. PubMed ID: 31541309
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Osimertinib vs Docetaxel-bevacizumab in Third-line Treatment in EGFR T790M Resistance Mutation Advanced Non-Small Cell Lung Cancer in China.
Rui M; Li H
Clin Ther; 2020 Nov; 42(11):2159-2170.e6. PubMed ID: 33028495
[TBL] [Abstract][Full Text] [Related]
10. Osimertinib in the treatment of resected EGFR-mutated non-small cell lung cancer: a cost-effectiveness analysis in the United States.
Huo G; Song Y; Liu W; Cao X; Chen P
Front Pharmacol; 2024; 15():1300183. PubMed ID: 38606181
[No Abstract] [Full Text] [Related]
11. Cost-Effectiveness of 12 First-Line Treatments for Patients With Advanced EGFR Mutated NSCLC in the United Kingdom and China.
Guan H; Wang C; Chen C; Han S; Zhao Z
Front Oncol; 2022; 12():819674. PubMed ID: 35785198
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of dacomitinib versus gefitinib for the first-line therapy of patients with EGFR mutation-positive non-small-cell lung cancer in the United States and China.
Xu X; Fang N; Li H; Liu Y; Yang F; Li X
Ann Transl Med; 2021 May; 9(9):760. PubMed ID: 34268373
[TBL] [Abstract][Full Text] [Related]
13. Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer.
Lemmon CA; Zabor EC; Pennell NA
Oncologist; 2022 May; 27(5):407-413. PubMed ID: 35285487
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China.
Liu Q; Luo X; Peng L; Yi L; Wan X; Zeng X; Tan C
BMJ Open; 2020 Nov; 10(11):e040691. PubMed ID: 33243806
[TBL] [Abstract][Full Text] [Related]
15. Long QT syndrome after using EGFR-TKIs in older patients with advanced non-small cell lung cancer.
Byun JY; Han S; Qdaisat A; Park C
Expert Opin Drug Saf; 2023 Dec; ():1-9. PubMed ID: 38088244
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Comparison Between Adjuvant Targeted Therapy and Chemotherapy for EGFR-Mutant NSCLC Patients: A Cost-Effectiveness Analysis.
Li W; Guo H; Li L; Cui J
Front Oncol; 2021; 11():619376. PubMed ID: 33842322
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR
Zhang Y; Zeng X; Deng H; Ma F; Peng Y; Yi L; Tan C; Peng L
Clin Ther; 2019 Jun; 41(6):1175-1185. PubMed ID: 31104762
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status.
Liu G; Kang S; Wang X; Shang F
Front Oncol; 2021; 11():669195. PubMed ID: 33987103
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness comparison of third-generation EGFR-TKI as initial and sequential therapy in adjuvant treatment for EGFR mutation-sensitive stage IIIA non-small cell lung cancer after surgery.
Ma W; Sheng Z; Niu Y; Yan B; Chen Y; Yang H; Li R
Heliyon; 2023 Nov; 9(11):e20955. PubMed ID: 37920491
[TBL] [Abstract][Full Text] [Related]
20. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
